Method Article
We have developed a flow cytometer using laser induced ultrasound to detect circulating melanoma cells as an early indicator of metastatic disease.
Circulating tumor cells (CTCs) are those cells that have separated from a macroscopic tumor and spread through the blood and lymph systems to seed secondary tumors1,2,3. CTCs are indicators of metastatic disease and their detection in blood samples may be used to diagnose cancer and monitor a patient′s response to therapy. Since CTCs are rare, comprising about one tumor cell among billions of normal blood cells in advanced cancer patients, their detection and enumeration is a difficult task. We exploit the presence of pigment in most melanoma cells to generate photoacoustic, or laser induced ultrasonic waves in a custom flow cytometer for detection of circulating melanoma cells (CMCs)4,5. This process entails separating a whole blood sample using centrifugation and obtaining the white blood cell layer. If present in whole blood, CMCs will separate with the white blood cells due to similar density. These cells are resuspended in phosphate buffered saline (PBS) and introduced into the flowmeter. Rather than a continuous flow of the blood cell suspension, we induced two phase flow in order to capture these cells for further study. In two phase flow, two immiscible liquids in a microfluidic system meet at a junction and form alternating slugs of liquid6,7. PBS suspended white blood cells and air form microliter slugs that are sequentially irradiated with laser light. The addition of a surfactant to the liquid phase allows uniform slug formation and the user can create different sized slugs by altering the flow rates of the two phases. Slugs of air and slugs of PBS with white blood cells contain no light absorbers and hence, do not produce photoacoustic waves. However, slugs of white blood cells that contain even single CMCs absorb laser light and produce high frequency acoustic waves. These slugs that generate photoacoustic waves are sequestered and collected for cytochemical staining for verification of CMCs.
1. Blood sample preparation
2. Flow Chamber Construction
3. Photoacoustic flowmetry set-up
4. Immunocytochemistry
5. Representative Results:
Figure 1.
The photoacoustic waveforms from white blood cells and melanoma cells are shown here. The white blood cells, having no inherent pigmentation, produce no photoacoustic waves and manifest as a flat line of electronic noise (left). The pigmented melanoma cells produces a robust photoacoustic wave (right).
Figure 2.
After immunocytochemical staining, cultured melanoma cells show DAPI signals in blue while MART1 is highlighted in green.
Figure 3.
Overlaying images for DAPI and MART1, as in Figure 2, with CD45 as an indicator of leukocytes, this figure shows melanoma cells among several white blood cells.
Detecting CTCs is still a research intensive field with very few clinical applications due to the difficult problem of isolating the rare tumor cells. Many other techniques are being evaluated for CTC detection, including RT-PCR, microfluidic cell capture, immunomagnetic capture, and other methods8-12. However, photoacoustic detection of CMCs shows promise as it is label free and provides a rapid and accurate means to capture small, light absorbing particles.
The protocol described to isolate white blood cells is highly efficient, yet a low number of red blood cells exist in the sample. These rouge contaminating cells also absorb laser light, but at a greatly decreased level. To ensure the red blood cells do not interfere with our melanoma detection system, five healthy patient samples were introduced through the system and none gave a signal, indicating that red blood cells are present at low enough concentrations to be disregarded.
A series of concentration studies have been conducted using cultured melanoma cells and the photoacoustic flow system has proven sensitive down to 1 cell/μL (unpublished data). These studies are on going and will soon include trials using cancer patient samples.
This photoacoustic technique is also being evaluated for use in non-pigmented CTCs, such as breast and prostate cancer by attaching exogenous chromophores. We have performed preliminary work using gold nanoparticles on cancer cells13. These tests have shown that nanoparticles can provide the necessary optical absorption to generate photoacoustic waves. The remaining technical challenge is to attach such particles to cancer cells selectively.
John A. Viator is founder and president of Viator Technologies Inc, a company formed to commercialize photoacoustic technologies for the improvement of human health.
We acknowledge the support of the Department of Biological Engineering and the Christopher S. Bond Life Sciences Center at the University of Missouri. We acknowledge grant support from Missouri Life Sciences Research Board 09-1034 and NIH R21CA139186-0. We also thank the Life Sciences Undergraduate Research Opportunity Program at the University of Missouri, the University of Missouri Molecular Cytology Core, and the University of Missouri College of Engineering for financial support.
Name | Company | Catalog Number | Comments |
DMEM | Invitrogen | ABCD1234 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone